Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9974724 | 0.90 | HDAC8 (0.47) | ROCK2ROCK1LMNAALDH1A1POLB | |
| SCHEMBL12284336 | 0.90 | MAPK8 (0.43) | P2RX7ROCK2ROCK1MAPK8LMNA | |
| SCHEMBL9974723 | 0.90 | LMNA (0.41) | P2RX7ROCK2ROCK1LMNAALDH1A1 | |
| SCHEMBL2419798 | 0.90 | GRIK1 (0.44) | ROCK2ROCK1MAPK8LMNABRD4 | |
| SCHEMBL2420703 | 0.89 | BRD4 (0.42) | ROCK2ROCK1LMNABRD4F2RL3 | |
| SCHEMBL9974663 | 0.88 | PTGS2 (0.45) | P2RX7ROCK2ROCK1MAPK8LMNA | |
| SCHEMBL2421586 | 0.87 | BRD4 (0.48) | LMNABRD4ALDH1A1POLB | |
| SCHEMBL9974704 | 0.85 | MAPK14 (0.46) | LMNAALDH1A1 | |
| SCHEMBL2422941 | 0.84 | MAPK14 (0.56) | BRD4 | |
| SCHEMBL2419000 | 0.84 | LMNA (0.39) | P2RX7LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144881-B1 | ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012979-B2 | Compounds and their uses 707 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008122765-A1 | NEW COMPOUNDS AND THEIR USES 707 | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023746-A1 | COMPOUNDS AND THEIR USES 707 | CYP3A7, UGT1A7, UGT2B7 | P2RX7 43/4885CFTR 196/4885OPRK1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.